MY196224A - Human Antibodies To Ebola Virus Glycoprotein - Google Patents
Human Antibodies To Ebola Virus GlycoproteinInfo
- Publication number
- MY196224A MY196224A MYPI2021007427A MYPI2021007427A MY196224A MY 196224 A MY196224 A MY 196224A MY PI2021007427 A MYPI2021007427 A MY PI2021007427A MY PI2021007427 A MYPI2021007427 A MY PI2021007427A MY 196224 A MY196224 A MY 196224A
- Authority
- MY
- Malaysia
- Prior art keywords
- ebola virus
- antibodies
- human antibodies
- virus glycoprotein
- bind
- Prior art date
Links
- 241001115402 Ebolavirus Species 0.000 title abstract 4
- 102000003886 Glycoproteins Human genes 0.000 title abstract 2
- 108090000288 Glycoproteins Proteins 0.000 title abstract 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000007501 viral attachment Effects 0.000 abstract 1
- 230000008478 viral entry into host cell Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107581P | 2015-01-26 | 2015-01-26 | |
| US201562161356P | 2015-05-14 | 2015-05-14 | |
| US201562245703P | 2015-10-23 | 2015-10-23 | |
| PCT/US2016/014720 WO2016123019A1 (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY196224A true MY196224A (en) | 2023-03-23 |
Family
ID=55300806
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021007427A MY196224A (en) | 2015-01-26 | 2016-01-25 | Human Antibodies To Ebola Virus Glycoprotein |
| MYPI2019007583A MY189452A (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
| MYPI2017702504A MY180045A (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
| MYPI2023001378A MY208081A (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019007583A MY189452A (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
| MYPI2017702504A MY180045A (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
| MYPI2023001378A MY208081A (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9771414B2 (enExample) |
| EP (2) | EP3250591B1 (enExample) |
| JP (4) | JP6829199B2 (enExample) |
| KR (1) | KR102641731B1 (enExample) |
| CN (2) | CN107667115B (enExample) |
| AU (2) | AU2016211783B2 (enExample) |
| BR (1) | BR112017015845A2 (enExample) |
| CA (1) | CA2974899A1 (enExample) |
| CL (3) | CL2017001920A1 (enExample) |
| CO (1) | CO2017007619A2 (enExample) |
| DK (1) | DK3250591T3 (enExample) |
| EA (1) | EA038993B1 (enExample) |
| FI (1) | FI3250591T3 (enExample) |
| IL (1) | IL253358B (enExample) |
| LT (1) | LT3250591T (enExample) |
| MA (1) | MA41421A (enExample) |
| MX (2) | MX392533B (enExample) |
| MY (4) | MY196224A (enExample) |
| PH (1) | PH12017501277B1 (enExample) |
| PT (1) | PT3250591T (enExample) |
| SG (2) | SG10202007835QA (enExample) |
| SM (1) | SMT202500454T1 (enExample) |
| TW (1) | TWI710573B (enExample) |
| UY (1) | UY36538A (enExample) |
| WO (1) | WO2016123019A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102198A1 (es) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | Proceso para reducir partículas subvisibles en una formulación farmacéutica |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EP3487521A4 (en) | 2016-07-21 | 2020-07-01 | Emory University | ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM |
| JP2019529350A (ja) | 2016-08-16 | 2019-10-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 混合物から個々の抗体を定量する方法 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| BR112019006689A2 (pt) | 2016-10-25 | 2019-06-25 | Regeneron Pharma | métodos e sistemas para análise de dados de cromatografia |
| CN108570106B (zh) * | 2017-03-10 | 2021-07-16 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
| KR20250041082A (ko) | 2017-07-06 | 2025-03-25 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| WO2019139648A2 (en) * | 2017-09-15 | 2019-07-18 | David Weiner | Dna antibody constructs for use against ebola virus |
| KR102798879B1 (ko) | 2017-09-19 | 2025-04-30 | 리제너론 파아마슈티컬스, 인크. | 입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물 |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| RU2686630C1 (ru) * | 2017-12-22 | 2019-04-29 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire) |
| EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| WO2019136029A1 (en) * | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| WO2019152607A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against ebola virus |
| JP7349998B2 (ja) | 2018-01-31 | 2023-09-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| JP2021514609A (ja) | 2018-02-28 | 2021-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ウイルス混入物質を同定するためのシステムおよび方法 |
| CN108373500A (zh) * | 2018-03-12 | 2018-08-07 | 中国科学院微生物研究所 | 一种热稳定性埃博拉治疗性抗体的制备及应用 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| MY202358A (en) | 2018-03-19 | 2024-04-24 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
| JP7382950B2 (ja) * | 2018-03-26 | 2023-11-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ＰｆＲＨ５抗体およびその抗原結合断片 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| US11939370B2 (en) | 2018-07-12 | 2024-03-26 | Vanderbilt University | Pan-ebola virus neutralizing human antibodies and methods of use therefor |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| EP3774841A1 (en) | 2018-08-27 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| CA3100038A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| CN111138526B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 |
| CN111138528B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 |
| CN111138527B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
| CN111138531B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 |
| BR112021009543A2 (pt) | 2019-01-16 | 2021-08-17 | Regeneron Pharmaceuticals, Inc. | métodos para identificar tióis livres em um medicamento de proteína, de identificação de heterogeneidade de dissulfeto em um medicamento de proteína e para selecionar um medicamento de proteína, e, composição farmacêutica |
| JP7662157B2 (ja) | 2019-02-08 | 2025-04-15 | ウィスコンシン アルムニ リサーチ ファンデイション | ヒト化細胞系 |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
| JP7627911B2 (ja) | 2019-08-27 | 2025-02-07 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| GB201917480D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
| WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| CN115243718A (zh) | 2020-01-24 | 2022-10-25 | 瑞泽恩制药公司 | 稳定的抗体制剂 |
| US11739303B2 (en) | 2020-01-24 | 2023-08-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized NA |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| DK3872091T5 (da) | 2020-02-26 | 2024-08-12 | Vir Biotechnology Inc | Antistoffer mod sars-cov-2 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2022015656A1 (en) * | 2020-07-13 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| WO2022074630A1 (en) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Liquid oral suspension of favipiravir |
| US12239687B2 (en) | 2020-11-25 | 2025-03-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| US11834493B2 (en) * | 2021-01-05 | 2023-12-05 | Immunome, Inc. | Antibody cocktail against SARS-CoV-2 spike protein |
| AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| EP4405390A1 (en) | 2021-09-20 | 2024-07-31 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
| WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| IL312372A (en) | 2021-10-26 | 2024-06-01 | Regeneron Pharma | Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures |
| WO2023137443A1 (en) | 2022-01-14 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| CN120623329A (zh) * | 2025-01-15 | 2025-09-12 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US8513391B2 (en) | 2008-02-01 | 2013-08-20 | Steven Jones | Monoclonal antibodies for Ebola and Marburg viruses |
| EP3351628B1 (en) | 2008-10-24 | 2023-07-26 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Human ebola virus species and compositions and methods thereof |
| SG176251A1 (en) | 2009-06-02 | 2011-12-29 | Regeneron Pharma | Fucosylation-deficient cells |
| KR102010827B1 (ko) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| EP2473525A4 (en) | 2009-09-02 | 2013-08-21 | Us Army | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS |
| US9346875B2 (en) | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
| AU2015218905A1 (en) | 2014-02-19 | 2016-08-04 | Emergent Biosolutions Canada Inc. | Ebola monoclonal antibodies |
| CN103864904B (zh) * | 2014-03-04 | 2016-01-20 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
| WO2015200522A2 (en) | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| US10435461B2 (en) | 2014-08-20 | 2019-10-08 | Albert Einstein College Of Medicine | Therapy for filovirus infection |
| US10894818B2 (en) | 2014-10-03 | 2021-01-19 | Massachusetts Institute Of Technology | Antibodies that bind Ebola glycoprotein and uses thereof |
| US10640549B2 (en) | 2014-10-17 | 2020-05-05 | University Of Virginia Patent Foundation | Recombinant antibodies that recognize the C-terminal domains of Ebola virus nucleoprotein |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
-
2016
- 2016-01-22 TW TW105101967A patent/TWI710573B/zh active
- 2016-01-24 MA MA041421A patent/MA41421A/fr unknown
- 2016-01-25 AU AU2016211783A patent/AU2016211783B2/en active Active
- 2016-01-25 BR BR112017015845A patent/BR112017015845A2/pt active Search and Examination
- 2016-01-25 CA CA2974899A patent/CA2974899A1/en active Pending
- 2016-01-25 MY MYPI2021007427A patent/MY196224A/en unknown
- 2016-01-25 LT LTEPPCT/US2016/014720T patent/LT3250591T/lt unknown
- 2016-01-25 US US15/005,334 patent/US9771414B2/en active Active
- 2016-01-25 SG SG10202007835QA patent/SG10202007835QA/en unknown
- 2016-01-25 MY MYPI2019007583A patent/MY189452A/en unknown
- 2016-01-25 SG SG11201705681YA patent/SG11201705681YA/en unknown
- 2016-01-25 DK DK16703030.3T patent/DK3250591T3/da active
- 2016-01-25 CN CN201680018389.XA patent/CN107667115B/zh active Active
- 2016-01-25 WO PCT/US2016/014720 patent/WO2016123019A1/en not_active Ceased
- 2016-01-25 MY MYPI2017702504A patent/MY180045A/en unknown
- 2016-01-25 KR KR1020177021579A patent/KR102641731B1/ko active Active
- 2016-01-25 MX MX2017009716A patent/MX392533B/es unknown
- 2016-01-25 PH PH1/2017/501277A patent/PH12017501277B1/en unknown
- 2016-01-25 EP EP16703030.3A patent/EP3250591B1/en active Active
- 2016-01-25 SM SM20250454T patent/SMT202500454T1/it unknown
- 2016-01-25 EP EP25206939.8A patent/EP4653051A2/en active Pending
- 2016-01-25 MY MYPI2023001378A patent/MY208081A/en unknown
- 2016-01-25 PT PT167030303T patent/PT3250591T/pt unknown
- 2016-01-25 FI FIEP16703030.3T patent/FI3250591T3/fi active
- 2016-01-25 EA EA201791675A patent/EA038993B1/ru unknown
- 2016-01-25 CN CN202110499070.6A patent/CN113354732B/zh active Active
- 2016-01-25 JP JP2017536549A patent/JP6829199B2/ja active Active
- 2016-01-26 UY UY0001036538A patent/UY36538A/es active IP Right Grant
-
2017
- 2017-07-09 IL IL253358A patent/IL253358B/en unknown
- 2017-07-26 MX MX2021015687A patent/MX2021015687A/es unknown
- 2017-07-26 CL CL2017001920A patent/CL2017001920A1/es unknown
- 2017-07-27 CO CONC2017/0007619A patent/CO2017007619A2/es unknown
- 2017-08-28 US US15/688,474 patent/US10081670B2/en active Active
-
2018
- 2018-08-22 US US16/108,096 patent/US10501526B2/en active Active
-
2019
- 2019-10-24 US US16/663,261 patent/US10829544B2/en active Active
-
2020
- 2020-02-28 CL CL2020000498A patent/CL2020000498A1/es unknown
- 2020-05-07 JP JP2020081768A patent/JP7672200B2/ja active Active
- 2020-09-30 US US17/039,557 patent/US11530255B2/en active Active
-
2021
- 2021-05-05 AU AU2021202839A patent/AU2021202839A1/en not_active Abandoned
-
2022
- 2022-11-09 US US18/053,927 patent/US12152067B2/en active Active
- 2022-12-26 CL CL2022003763A patent/CL2022003763A1/es unknown
-
2023
- 2023-03-07 JP JP2023034449A patent/JP2023065648A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019929A patent/JP7796918B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY196224A (en) | Human Antibodies To Ebola Virus Glycoprotein | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| PH12017500949A1 (en) | Human antibodies to influenza hemagglutinin | |
| MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| GEP20217328B (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
| EA201791525A3 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| MY207220A (en) | Anti-hemagglutinin antibodies and methods of use thereof | |
| PH12017501943A1 (en) | Influenza virus neutralizing peptidomimetic compounds | |
| HK1240605A1 (en) | Human antibodies to ebola virus glycoprotein | |
| EA202191973A2 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| HK1238655A1 (en) | Human antibodies to influenza hemagglutinin | |
| WO2017211843A8 (en) | ANTIVIRAL POLYCLONAL ANTIBODIES AGAINST EBOLA VIRUS AND USES THEREOF | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| AR104480A1 (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
| WO2013024156A3 (en) | Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |